In the BioHarmony Drug Report Database

"Preview" Icon

Pitolisant

Wakix (pitolisant) is a small molecule pharmaceutical. Pitolisant was first approved as Wakix on 2016-03-31. It has been approved in Europe to treat narcolepsy. The pharmaceutical is active against histamine H3 receptor. In addition, it is known to target histamine H4 receptor, histamine H2 receptor, and histamine H1 receptor. Wakix’s patents are valid until 2029-09-26 (FDA).

 

Trade Name

 

Wakix
 

Common Name

 

pitolisant
 

ChEMBL ID

 

CHEMBL462605
 

Indication

 

narcolepsy
 

Drug Class

 

Histamine H3 receptor antagonists

Image (chem structure or protein)

Pitolisant structure rendering